Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
177Lu-P17-088 in mAPMR Prostate Cancer
NCT07562438Phase 2Active, not recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Apr 2026
- Primary completion
- Jun 2027
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 177Lu-P17-088 in castration-resistant prostate cancer (CRPC), sponsored by The First Hospital of Fujian Medical University. Primary endpoints: Prostate-specific antigen 50 response at 50 months, Treatment Emergent Adverse Events at 50 months and 1 more. Started Apr 2026; status: active, not recruiting.
02
Drugs
177Lu-P17-088
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07562438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07562438.